1. Home
  2. ROIV

as of 11-20-2026 3:45pm EST

$38.91
$0.05
-0.12%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.

Founded: 2014 Country:
United Kingdom
United Kingdom
Employees: N/A City: LONDON
Market Cap: 28.7B IPO Year: 2021
Target Price: $50.82 AVG Volume (30 days): 7.1M
Analyst Decision: Strong Buy Number of Analysts: 13
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -0.53 EPS Growth: -125.00
52 Week Low/High: $19.96 - $42.50 Next Earning Date: 11-09-2026
Revenue: $8,260,000 Revenue Growth: -71.57%
Revenue Growth (this year): 1870.25% Revenue Growth (next year): 271.46%
P/E Ratio: -73.49 Index: N/A
Free Cash Flow: -758558000.0 FCF Growth: N/A

Stock Insider Trading Activity of Roivant Sciences Ltd. (ROIV)

ROIV Nov 11, 2026

Avg Cost/Share

$41.80

Shares

175,000

Total Value

$7,323,271.90

Owned After

351,851

SEC Form 4

Form 1 Form 2
ROIV Nov 10, 2026

Avg Cost/Share

$41.20

Shares

125,000

Total Value

$5,150,000.00

Owned After

351,851

SEC Form 4

Venker Eric

President & Immunovant CEO

Sell
ROIV Nov 10, 2026

Avg Cost/Share

$40.72

Shares

187,943

Total Value

$7,617,074.36

Owned After

811,211

Venker Eric

President & Immunovant CEO

Sell
ROIV Nov 3, 2026

Avg Cost/Share

$36.31

Shares

200,000

Total Value

$7,262,000.00

Owned After

811,211

SEC Form 4

Venker Eric

President & Immunovant CEO

Sell
ROIV Oct 28, 2026

Avg Cost/Share

$36.59

Shares

200,000

Total Value

$7,318,000.00

Owned After

811,211

SEC Form 4

Venker Eric

President & Immunovant CEO

Sell
ROIV Oct 20, 2026

Avg Cost/Share

$35.26

Shares

200,000

Total Value

$7,022,667.52

Owned After

811,211

Sell
ROIV Oct 1, 2026

Avg Cost/Share

$36.33

Shares

17,750

Total Value

$640,861.00

Owned After

14,954

Sell
ROIV Sep 15, 2026

Avg Cost/Share

$40.07

Shares

5,112

Total Value

$203,152.16

Owned After

36,508

Sell
ROIV Sep 15, 2026

Avg Cost/Share

$40.02

Shares

4,938

Total Value

$196,229.70

Owned After

14,954

Sell
ROIV Sep 8, 2026

Avg Cost/Share

$39.90

Shares

20,000

Total Value

$798,000.00

Owned After

36,508

SEC Form 4

Earnings Transcripts

SEC 8-K filings with transcript text

View All
2026
Q3

Q3 2026 Earnings

8-K SELL

Nov 9, 2026 · 100% conf.

AI Prediction SELL

1D

-0.27%

$40.28

Act: +2.28%

5D

-5.16%

$38.31

20D

+1.17%

$40.87

Price: $40.40 Prob +5D: 0% AUC: 1.000
0001635088-26-000130

roiv-20261109

false000163508800016350882026-11-092026-11-09

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): November 9, 2026

Roivant Sciences Ltd.

(Exact Name of Registrant as Specified in Charter)

Bermuda001-4078298-1173944

(State or Other Jurisdiction of Incorporation)(Commission File Number)(I.R.S. Employer Identification No.)

7th Floor

50 Broadway

London SW1H 0DB

United Kingdom

(Addresses of Principal Executive Offices, and Zip Code)

+44 207 400 3347

Registrant’s Telephone Number, Including Area Code

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

oWritten communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered

Common Shares, $0.0000000341740141 per shareROIV The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 2.02    Results of Operations and Financial Condition.

On November 9, 2026, Roivant Sciences Ltd. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended September 30, 2026. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

The information set forth under this “Item 2.02 Results of Operations and Financial Condition” (including Exhibit 99.1) shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference in any filing made by the Company pursuant to the Securities Act of 1933, as amended, other than to the extent that such filing incorporates by reference any or all of such information by express reference thereto.

Item 9.01    Financial Statements and Exhibits.

(d)Exhibits.

Exhibit No.Description of Exhibit

99.1 Roivant Science Ltd. Press Release, dated November 9, 2026

104Cover Page Interactive Data File (embedded with Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ROIVANT SCIENCES LTD.

By: /s/ Keyur Parekh

Name: Keyur Parekh

Title: Authorized Signatory

Dated: November 9, 2026

2026
Q2

Q2 2026 Earnings

8-K BUY

Aug 6, 2026 · 100% conf.

AI Prediction BUY

1D

+2.65%

$36.05

Act: +3.47%

5D

+3.97%

$36.52

20D

+9.51%

$38.46

Price: $35.12 Prob +5D: 100% AUC: 1.000
0001635088-26-000088

roiv-20260806

false000163508800016350882026-08-062026-08-06

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): August 6, 2026

Roivant Sciences Ltd.

(Exact Name of Registrant as Specified in Charter)

Bermuda001-4078298-1173944

(State or Other Jurisdiction of Incorporation)(Commission File Number)(I.R.S. Employer Identification No.)

7th Floor

50 Broadway

London SW1H 0DB

United Kingdom

(Addresses of Principal Executive Offices, and Zip Code)

+44 207 400 3347

Registrant’s Telephone Number, Including Area Code

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

oWritten communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered

Common Shares, $0.0000000341740141 per shareROIV The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 2.02    Results of Operations and Financial Condition.

On August 6, 2026, Roivant Sciences Ltd. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended June 30, 2026. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

The information set forth under this “Item 2.02 Results of Operations and Financial Condition” (including Exhibit 99.1) shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference in any filing made by the Company pursuant to the Securities Act of 1933, as amended, other than to the extent that such filing incorporates by reference any or all of such information by express reference thereto.

Item 9.01    Financial Statements and Exhibits.

(d)Exhibits.

Exhibit No.Description of Exhibit

99.1 Roivant Science Ltd. Press Release, dated August 6, 2026

104Cover Page Interactive Data File (embedded with Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ROIVANT SCIENCES LTD.

By: /s/ Keyur Parekh

Name: Keyur Parekh

Title: Authorized Signatory

Dated: August 6, 2026

2026
Q1

Q1 2026 Earnings

8-K SELL

May 20, 2026 · 100% conf.

AI Prediction SELL

1D

+0.22%

$32.48

Act: -4.72%

5D

-4.85%

$30.84

Act: -7.87%

20D

+1.90%

$33.03

Act: -3.02%

Price: $32.41 Prob +5D: 0% AUC: 1.000
0001635088-26-000060

roiv-20260520

false000163508800016350882026-05-202026-05-200001635088roiv:WhollyOwnedSubsidiariesAddressNYMember2026-05-202026-05-200001635088roiv:WhollyOwnedSubsidiariesAddressSwitzerlandMember2026-05-202026-05-20

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): May 20, 2026

Roivant Sciences Ltd.

(Exact Name of Registrant as Specified in Charter)

Bermuda001-4078298-1173944

(State or Other Jurisdiction of Incorporation)(Commission File Number)(I.R.S. Employer Identification No.)

7th Floor

50 Broadway

London SW1H 0DB

United Kingdom

1 Pennsylvania Plaza

Floor 54

New York, NY 10119 United States1

Viaduktstrasse 8

4051 Basel

Switzerland1

(Addresses of Principal Executive Offices, and Zip Code)

+44 207 400 3347

Registrant’s Telephone Number, Including Area Code

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

oWritten communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered

Common Shares, $0.0000000341740141 per shareROIV The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

1 Addresses of wholly-owned subsidiaries of the Registrant.

Item 2.02    Results of Operations and Financial Condition.

On May 20, 2026, Roivant Sciences Ltd. (the “Company”) issued a press release announcing its financial results for the fourth quarter and fiscal year ended March 31, 2026. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

The information set forth under this “Item 2.02 Results of Operations and Financial Condition” (including Exhibit 99.1) shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference in any filing made by the Company pursuant to the Securities Act of 1933, as amended, other than to the extent that such filing incorporates by reference any or all of such information by express reference thereto.

Item 9.01    Financial Statements and Exhibits.

(d)Exhibits.

Exhibit No.Description of Exhibit

99.1 Roivant Science Ltd. Press Release, dated May 20, 2026

104Cover Page Interactive Data File (embedded with Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ROIVANT SCIENCES LTD.

By: /s/ Keyur Parekh

Name: Keyur Parekh

Title: Authorized Signatory

Dated: May 20, 2026

Share on Social Networks: